Unique ID issued by UMIN | UMIN000001379 |
---|---|
Receipt number | R000001677 |
Scientific Title | Prospective randomized controlled study for the therapeutic effect of removing uremic toxins on endothelial function in undialyzed patients with chronic renal failure |
Date of disclosure of the study information | 2008/10/01 |
Last modified on | 2011/03/17 12:53:44 |
Prospective randomized controlled study for the therapeutic effect of removing uremic toxins on endothelial function in undialyzed patients with chronic renal failure
Effect of removing uremic toxins on endothelial function
Prospective randomized controlled study for the therapeutic effect of removing uremic toxins on endothelial function in undialyzed patients with chronic renal failure
Effect of removing uremic toxins on endothelial function
Japan |
Undialyzed patients with chronic renal failure
Medicine in general | Cardiology | Nephrology |
Others
NO
To evaluate the therapeutic effect of removing uremic toxins by oral adsorbent AST-120 on endothelial function in undialyzed patients with chronic renal failure
Efficacy
Exploratory
Pragmatic
Not applicable
Flow-mediated vasodilation of branchial artery
Changes of the below parameters:
(1) Systolic and diastolic blood pressure
(2) Creatinine clearance (Ccr)
(3) Urinary protein excretion (UPE)
(4) Mediators associated with endothelial function
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Treated by AST-120 6g daily for a period of 6 months
Not treated by AST-120 for a period of 6 months
20 | years-old | <= |
Not applicable |
Male and Female
(1) Medications have not been changed in the last 6 months.
(2) Blood pressures have been controlled appropriately in the last 6 months.
(3) HbA1c levels have been stable within +/-0.5% changes in the last 6 months.
(4) Over 20 years of age.
(5) Patients with the informed consent to this study.
(1) Patients with obstructive or stenotic diseases of digestive organs.
(2) Patients with the nephrotic syndrome.
(3) Patients with acute renal failure, rapid elevation of serum creatinine or active nephropahty in the last 6 months.
(4) Patients with inflammatory or consumptive diseases (e.g. infection, malignancy).
(5) Patients with severe cardiovascular diseases (e.g. heart failure, coronary disease, cerebrovascular disease, peripheral vascular disease).
(6) Dialyzed patients.
(7) Patients treated by AST-120.
(8) Patients treated by steroids or immunosuppressive agents.
(9) Females in pregnancy.
(10) Patients judged as unsuitable for participating in this study by the attending physician.
30
1st name | |
Middle name | |
Last name | Norio Komai |
Kawasaki Medical School
Division of Nephrology, Department of Internal Medicine
577 Matsushima, Kurashiki, Okayama 701-0192
086-462-1111
1st name | |
Middle name | |
Last name | Yuko Nishi |
Kawasaki Medical School
Division of Nephrology, Department of Internal Medicine
577 Matsushima, Kurashiki, Okayama 701-0192
086-462-1111
yuko-n77@med.kawasaki-m.ac.jp
Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School
None
Self funding
None
None
None
NO
2008 | Year | 10 | Month | 01 | Day |
Unpublished
Completed
2008 | Year | 09 | Month | 08 | Day |
2009 | Year | 01 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2008 | Year | 09 | Month | 17 | Day |
2011 | Year | 03 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001677